TABLE 2.

Results of clinical trials on the role of vitamin D in the treatment of SARS-CoV2 infections.

No	Author (year)	Intervention	Dose of vitamin D	Results
1	Lakkireddy et al. (2021)	Daily supplementation of vitamin D for 8 or 10 days (depending upon BMI) or not	60,000 IU	Reduction of inflammatory markers: N/L ratio, CRP, LDH, IL6, Ferritin
2	Sabico et al. (2021)	Daily supplementation of two doses of vitamin D for 2 weeks	5,000 IU vs. 1,000 IU	Reduction the time to recovery for cough and gustatory sensory loss in group 5000 IU supplementation
3	Alcala-Diaz et al. (2021)	Treatment of calcifediol (double dose on entry and then one dose on day 3, 7, 14, 21, and 28) or not	0.266 mg calcifediol	Treatment with calcifediol was associated with lower in-hospital mortality
4	Maghbooli et al. (2021)	Treatment with calcifediol (one dose for 60 days) or placebo	25 μg calcifediol	Treatment with calcifediol was associated with increase in the lymphocyte percentage and decrease in the neutrophil-to-lymphocyte ratio
5	Elamir et al. (2021)	Treatment with calcitriol (one dose daily for 14 days or hospital discharge) or not	0.5 μg calcitriol	Improvement in oxygenation among patients treated with calcitriol
6	Murai Et al (2021)	Receive a single high dose of vitamin D3 or placebo	200,000 IU	Not significantly reduce hospital length of stay, in-hospital mortality, admission to the intensive care unit or need for mechanical ventilation
7	Castillo et al.(2020)	Treatment of calcifediol (double dose on entry and then one dose on day 3, 7) or placebo	0.266 mg calcifediol	Treatment with calcifediol was associated with less often the stay in the Intensive Care Unit